Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer, Cancer, Cancer, Hematology, Urology |
| Therapuetic Areas: | Hematology, Nephrology / Urology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 3/15/2019 |
| Start Date: | February 26, 2018 |
| End Date: | December 31, 2030 |
| Contact: | Yolanda McKinney, R.N. |
| Email: | ymckinney@mail.nih.gov |
| Phone: | (240) 760-6095 |
Background:
Prostate cancer is one of the most common cancers for men in the U.S. There are some new ways
to take pictures of the cancer. There are also new ways to use image-guided biopsy and
therapy. These could help manage prostate cancer. Researchers want to study how imaging can
provide a profile of prostate cancer. They want to collect data to make diagnosis and
treatments better.
Objectives:
To gather data about the radiological and clinical course of prostate cancer. To study
imaging-based biomarkers of prostate cancer.
Eligibility:
Men ages 18 and older with diagnosed or suspected prostate cancer
Design:
Participants will give permission for researchers to use their medical history and records.
Their data will be reviewed, collected, and analyzed. These include results of their tests
and scans.
Sponsoring Institution: National Cancer Institute
Prostate cancer is one of the most common cancers for men in the U.S. There are some new ways
to take pictures of the cancer. There are also new ways to use image-guided biopsy and
therapy. These could help manage prostate cancer. Researchers want to study how imaging can
provide a profile of prostate cancer. They want to collect data to make diagnosis and
treatments better.
Objectives:
To gather data about the radiological and clinical course of prostate cancer. To study
imaging-based biomarkers of prostate cancer.
Eligibility:
Men ages 18 and older with diagnosed or suspected prostate cancer
Design:
Participants will give permission for researchers to use their medical history and records.
Their data will be reviewed, collected, and analyzed. These include results of their tests
and scans.
Sponsoring Institution: National Cancer Institute
Background:
- Multiparametric MRI (mpMRI) has become an established method for localizing clinically
significant prostate cancer, and identification of imaging-based prognostic markers
represents an active research area.
- Multiple treatments are available for patients with localized prostate cancer, including
radical prostatectomy, external beam radiotherapy, brachytherapy, and focal ablation;
however, therapy-specific indication and imaging-based response biomarkers are poorly
understood.
- As mpMRI is considered a standard of care , there is no patient consent for research
related to imaging biomarkers and their correlation with other clinical and pathologic
features.
- Translation of imaging, clinical, and pathological-based features into treatment
decisions has yet to be fully characterized for development of a decision-support
system.
- Therefore, the purpose of this protocol is to enable the collection of data to enable
research in the development of computer aided diagnosis, decision support and deep
learning/artificial intelligence research.
Objective:
- To evaluate radiological profiling of patients with prostate cancer in support of the
Molecular Imaging Branch (MIB) for identification of imaging-based prognostic markers in
prostate cancer.
Eligibility:
- Patients with a diagnosis of prostatic cancer or suspicious for prostatic cancer
lesions.
- Age greater than or equal to 18 years.
Design:
- Imaging evaluation and clinical profiling of patients with or suspected of prostate cancer
obtained during visits to NCI and long-term follow up will be collected and analyzed.
- Multiparametric MRI (mpMRI) has become an established method for localizing clinically
significant prostate cancer, and identification of imaging-based prognostic markers
represents an active research area.
- Multiple treatments are available for patients with localized prostate cancer, including
radical prostatectomy, external beam radiotherapy, brachytherapy, and focal ablation;
however, therapy-specific indication and imaging-based response biomarkers are poorly
understood.
- As mpMRI is considered a standard of care , there is no patient consent for research
related to imaging biomarkers and their correlation with other clinical and pathologic
features.
- Translation of imaging, clinical, and pathological-based features into treatment
decisions has yet to be fully characterized for development of a decision-support
system.
- Therefore, the purpose of this protocol is to enable the collection of data to enable
research in the development of computer aided diagnosis, decision support and deep
learning/artificial intelligence research.
Objective:
- To evaluate radiological profiling of patients with prostate cancer in support of the
Molecular Imaging Branch (MIB) for identification of imaging-based prognostic markers in
prostate cancer.
Eligibility:
- Patients with a diagnosis of prostatic cancer or suspicious for prostatic cancer
lesions.
- Age greater than or equal to 18 years.
Design:
- Imaging evaluation and clinical profiling of patients with or suspected of prostate cancer
obtained during visits to NCI and long-term follow up will be collected and analyzed.
- INCLUSION CRITERIA:
- Patients with a diagnosis of prostatic cancer or suspicious for prostatic cancer
lesions.
- Age greater than or equal to 18 years
- Ability of subject to understand and the willingness to sign a written informed
consent document.
- Subject must be enrolled on an NIH screening, diagnostic or treatment protocol
EXCLUSION CRITERIA:
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
301-496-2563
Phone: 888-624-1937
National Institutes of Health Clinical Center The National Institutes of Health (NIH) Clinical Center in...
Click here to add this to my saved trials
